Promoter and Institution shareholding in Welcure Drugs remains unchanged, indicating a lack of confidence from smart money.

Public shareholding surged by 78.99% YoY but declined by 3.27% QoQ, suggesting initial enthusiasm may be waning.

The sector averages also show no change, reinforcing a stagnant sentiment across both the stock and sector.